Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for alleged violations of securities laws, specifically related to misleading statements about the results of its PALISADE-2 trial of fasedienol [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from April 1, 2024, to December 16, 2025, with a deadline for lead plaintiff appointments set for March 16, 2026 [2]. - The complaint alleges that Vistagen made false and misleading statements regarding the success of its drug candidate, creating a false impression of a successful Phase 3 trial [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2][3].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc. for the period between April 1, 2024, and December 16, 2025, due to alleged misleading statements regarding the company's drug fasedienol [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen provided investors with overly positive information about the development and commercialization of fasedienol, an investigational drug for social anxiety disorder [5]. - Defendants allegedly made false and misleading statements while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to artificially inflated stock prices [6]. Group 2: Investor Information - Investors who purchased Vistagen common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][7]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - The complaint against Vistagen alleges violations of federal securities laws due to false or misleading statements regarding the Phase 3 PALISADE-3 trial of fasedienol for treating social anxiety disorder [2] Group 1: Company Performance - On December 17, 2025, Vistagen announced that its PALISADE-3 study did not meet its primary efficacy endpoint, failing to show statistically significant improvement in anxiety reduction compared to placebo [3] - Following the announcement, Vistagen's stock price dropped by $3.50, a decline of 80.27%, closing at $0.86 [3] Group 2: Legal Proceedings - The lead plaintiff in the class action is the investor with the largest financial interest in the case, who will oversee the litigation on behalf of the class [4] - Any member of the class can apply to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [4] Group 3: Whistleblower Information - The law firm Faruqi & Faruqi encourages individuals with information regarding Vistagen's conduct, including whistleblowers and former employees, to come forward [5]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc. for the period between April 1, 2024, and December 16, 2025, due to alleged misleading statements regarding the company's drug fasedienol [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen provided investors with overly positive information about the development and commercialization of fasedienol, an investigational drug for social anxiety disorder, while concealing material adverse facts about its Phase 3 PALISADE-3 trial [5][6]. - Investors are alleged to have purchased Vistagen common stock at artificially inflated prices due to these misleading statements, resulting in damages when the true information became public [6]. Group 2: Class Action Participation - Investors who purchased Vistagen Therapeutics common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][7]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action has been filed against Vistagen Therapeutics, Inc. for allegedly misleading investors regarding the viability of its Phase 3 trial study of fasedienol, leading to significant financial losses for shareholders [1][2]. Group 1: Allegations and Trial Results - Robbins LLP is investigating allegations that Vistagen Therapeutics misled investors about the success of its Phase 3 PALISADE-3 trial of fasedienol, which was intended for treating social anxiety disorder [2]. - On December 17, 2025, Vistagen announced that the PALISADE-3 trial did not show a statistically significant improvement on its primary endpoint, leading to a dramatic stock price decline from $4.36 to $0.86, a drop of over 80% [3]. Group 2: Class Action Participation - Shareholders who purchased Vistagen's common stock between April 1, 2024, and December 16, 2025, may be eligible to participate in the class action and can contact Robbins LLP to serve as lead plaintiff [1][4]. - Participation in the class action is not mandatory for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropsychiatric and neurological disorders [1].

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. on behalf of purchasers of its common stock between April 1, 2024, and December 16, 2025, due to misleading statements regarding the company's drug fasedienol and its clinical trials [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen provided investors with overly positive information about the development and commercialization of fasedienol, an investigational drug for social anxiety disorder, while concealing material adverse facts about its Phase 3 PALISADE-3 trial [5][6]. - Investors are eligible for compensation without any out-of-pocket fees through a contingency fee arrangement if they purchased Vistagen common stock during the class period [2][3]. Group 2: Legal Representation - The Rosen Law Firm, which has a strong track record in securities class actions, is representing the investors and encourages them to select qualified counsel [4]. - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly [3][7].

Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of purchasers of Vistagen Therapeutics, Inc. common stock during the specified class period from April 1, 2024, to December 16, 2025, indicating potential legal issues surrounding the company [1] Company Summary - Vistagen Therapeutics, Inc. is identified as a clinical-stage biopharmaceutical company, which suggests its focus on developing new therapeutic solutions [1]

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Vistagen Therapeutics, Inc. for alleged misrepresentations related to the company's Phase 3 PALISADE-3 trial of fasedienol, which is being developed for the treatment of social anxiety disorder [1][2]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased or acquired Vistagen's common stock between April 1, 2024, and December 16, 2025 [1]. - Defendants are accused of making false statements regarding the Phase 3 trial of fasedienol, an investigational drug [2]. Group 2: Lead Plaintiff Information - Interested parties wishing to serve as lead plaintiff must file papers by March 16, 2026 [3]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery from the lawsuit [3]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times [4].

Core Viewpoint - Investors in Vistagen Therapeutics, Inc. have the opportunity to lead a securities fraud lawsuit against the company with the Schall Law Firm [1] Group 1 - The lawsuit is centered around allegations of securities fraud involving Vistagen Therapeutics, Inc. [1] - The Schall Law Firm is actively seeking investors who wish to participate in the lawsuit [1] - This legal action presents a potential avenue for investors to address grievances related to the company's practices [1]

Core Viewpoint - A securities class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its Phase 3 PALISADE-3 trial of fasedienol, leading to significant stock price decline [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of individuals or entities that acquired Vistagen securities between April 1, 2024, and December 16, 2025 [1]. - The Complaint alleges that Vistagen made overwhelmingly positive statements while concealing material adverse facts about the PALISADE-3 trial [2]. Group 2: Trial Results - The PALISADE-3 Phase 3 study did not show a statistically significant improvement on the primary endpoint, which was the change on the Subjective Units of Distress Scale (SUDS) [2]. - The trial results indicated no treatment difference between fasedienol and placebo for the secondary endpoints [2]. Group 3: Market Reaction - Following the announcement of the trial results, Vistagen's stock price plummeted from $4.36 per share on December 16, 2025, to $0.86 per share on December 17, 2025, marking a decline of over 80% [3].